Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker (dihydropyridine) presented as an intravenous solution for use in patients at risk of cerebral vasospasm following subarachnoid hemorrhage. By selectively inhibiting L‑type calcium channels in cerebral arteries, it helps maintain adequate blood flow and reduces the likelihood of delayed ischemic neurological deficits.

GNH USA supplies Nimotop as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Nimodipine is used in the management of cerebrovascular disorders, particularly to prevent vasospasm after subarachnoid hemorrhage. - Aneurysmal subarachnoid hemorrhage: Prevention of cerebral vasospasm, lowering risk of delayed ischemic deficits. - Traumatic subarachnoid hemorrhage: Reduces incidence of vasospasm and associated neurological complications. - Cerebral vasospasm of any etiology: Mitigation of vessel narrowing to preserve cerebral perfusion.

Nimodipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: transient drop in blood pressure. - Nausea: occasional gastrointestinal upset. - Flushing: warm sensation with skin reddening. - Dizziness: feeling of light‑headedness.

Serious or Rare Side Effects: - Severe hypotension: may require medical intervention. - Bradycardia: markedly reduced heart rate. - Allergic reaction: rash, pruritus, or anaphylaxis. - Hepatic enzyme elevation: abnormal liver function tests.

Before initiating Nimodipine therapy, clinicians should consider several safety measures. - Monitor blood pressure: watch for symptomatic hypotension. - Assess hepatic function: adjust use if significant liver impairment is present. - Avoid concurrent potent vasodilators: risk of additive blood pressure lowering. - Use with caution in elderly patients: increased sensitivity to hemodynamic changes. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Nimodipine can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Other calcium channel blockers: additive cardiovascular depression. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increased plasma concentrations.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): reduced efficacy. - Non‑steroidal anti‑inflammatory drugs: may increase risk of renal impairment. - Beta‑blockers: potential enhancement of hypotensive effect.